Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: October 15, 2008
Reporting Period: Third Quarter 2008
This filing announces the results of operations for the third quarter of 2008. The detailed financial data is contained in a press release furnished as Exhibit 99.1 and incorporated by reference.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the referenced Exhibit 99.1 (Press Release).
The company utilizes non-GAAP financial measures to evaluate ongoing business performance, specifically:
- Net earnings excluding specified items.
- Diluted earnings per common share excluding specified items.
Adjustments are made for unusual or unpredictable factors, including acquisition-related costs, cost reduction initiatives, acquired in-process research and development, and gains/losses on certain investments.
Material Changes
The filing text does not explicitly detail material changes versus the prior comparable period. Investors must refer to the incorporated press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Risks
Management Commentary: Management states that non-GAAP measures provide useful information for evaluating ongoing performance and are used internally to monitor business results. However, the company cautions that these measures should be considered in addition to, and not as a substitute for, GAAP financial measures.
Guidance and Risks: The filing text does not contain specific forward-looking guidance, risk factors, or contingencies beyond the standard caution regarding non-GAAP measures.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2008 revenue, net earnings, and EPS figures.
- Compare GAAP results against the non-GAAP adjusted results to understand the impact of acquisition costs and other specified items.
- Verify the specific components excluded from non-GAAP calculations (e.g., in-process R&D, investment gains/losses).
- Check for any updated full-year guidance provided in the press release.